Patients with radiation-associated breast angiosarcoma may have an effective treatment option with the combination of oral paclitaxel with encequidar.
Patients with radiation-associated breast angiosarcoma may have an effective treatment option with the combination of oral paclitaxel with encequidar (oPac+E), according to study results presented during the 2020 San Antonio Breast Cancer Symposium.
The researchers assessed activity, safety and tolerability of oPac 205 mg/m2 plus E 12.9 mg once daily for 3 consecutive days weekly in patients with unresectable cutaneous angiosarcoma. The primary outcome of the study was tumor response to therapy every 6 weeks.
From August 2018 to May 2020, 7 patients (median age, 66 years; range, 49-76) were diagnosed with breast cutaneous angiosarcoma. All patients had previously been diagnosed with breast cancer and received a mastectomy and radiotherapy and/or adjuvant chemotherapy.
Three patients (43%) achieved a complete response on the combination, and also achieved stable disease (43%). One patient achieved a partial response to therapy. Forty-three percent of patients crossed over to receive curative surgical resection.
The combination was generally well tolerated, with grade 3 treatment-related adverse events (TRAEs) occurring in 5 patients. The most common grade 3 TRAEs included fatigue (2 cases), diarrhea, dyspnea, dehydration, pneumonitis and neutropenia (one case each). Three patients needed dose reductions, however there were no treatment discontinuations as a result of AEs. No patient deaths have been reported to date.
The authors concluded that the combination may be an effective oral treatment for patients with radiation-associated breast angiosarcoma, with limited toxicities, which could offer patients the potential to avoid intravenous chemotherapy at a hospital.
Reference
Ravi V, Wagner M, Chen TWW, et al. A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutaneous angiosarcoma: The breast angiosarcoma subgroup. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11; 2020; Virtual. Poster PS13-05.
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More